Precigen, Inc. (PGEN)
7.10
-0.04
(-0.56%)
USD |
NASDAQ |
Sep 04, 16:00
7.11
+0.01
(+0.14%)
After-Hours: 20:00
Precigen Research and Development Expense (Quarterly) : 6.963M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.963M |
| March 31, 2026 | 5.32M |
| December 31, 2025 | 6.672M |
| September 30, 2025 | 12.06M |
| June 30, 2025 | 11.17M |
| March 31, 2025 | 10.16M |
| December 31, 2024 | 11.44M |
| September 30, 2024 | 11.05M |
| June 30, 2024 | 14.48M |
| March 31, 2024 | 14.25M |
| December 31, 2023 | 12.99M |
| September 30, 2023 | 11.58M |
| June 30, 2023 | 11.87M |
| March 31, 2023 | 12.16M |
| December 31, 2022 | 10.79M |
| September 30, 2022 | 12.62M |
| June 30, 2022 | 11.95M |
| March 31, 2022 | 11.80M |
| December 31, 2021 | 12.18M |
| September 30, 2021 | 12.43M |
| June 30, 2021 | 13.18M |
| March 31, 2021 | 10.52M |
| December 31, 2020 | -3.609M |
| September 30, 2020 | 10.17M |
| June 30, 2020 | 9.474M |
| Date | Value |
|---|---|
| March 31, 2020 | 11.33M |
| December 31, 2019 | -14.18M |
| September 30, 2019 | 25.67M |
| June 30, 2019 | 28.24M |
| March 31, 2019 | 26.94M |
| December 31, 2018 | 273.23M |
| September 30, 2018 | 36.18M |
| June 30, 2018 | 42.05M |
| March 31, 2018 | 37.27M |
| December 31, 2017 | 38.54M |
| September 30, 2017 | 36.47M |
| June 30, 2017 | 34.01M |
| March 31, 2017 | 34.18M |
| December 31, 2016 | 29.02M |
| September 30, 2016 | 29.04M |
| June 30, 2016 | 28.38M |
| March 31, 2016 | 25.86M |
| December 31, 2015 | 26.20M |
| September 30, 2015 | 21.60M |
| June 30, 2015 | 20.38M |
| March 31, 2015 | 79.31M |
| December 31, 2014 | 14.10M |
| September 30, 2014 | 11.75M |
| June 30, 2014 | 12.51M |
| March 31, 2014 | 10.29M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 7.341M |
| Geron Corp. | 22.03M |
| Neurocrine Biosciences, Inc. | 326.70M |
| Aldeyra Therapeutics, Inc. | 3.484M |
| Elicio Therapeutics, Inc. | 6.775M |